Nelfinavir, sold under the brand name Viracept, is an antiretroviral medication used in the treatment of HIV/AIDS. Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and, like other PIs, it is almost always used in combination with other antiretroviral drugs.
Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.
Parent: Nelfinavir
Parent: Nelfinavir
Parent: Nelfinavir
Parent: Nelfinavir
![(3S,4aS,8aS)-2-[(2R,3R)-3-[(3-Amino-2-hydroxy-4-phenythiobutyl]-decahydro-N-(2-hydroxy-1,1-dimethylethyl)-3-isoquinolinecarboxamide](https://veeprho.com/wp-content/uploads/2024/09/VE0021639-N-2-hydroxy-1-1-dimethylethyl-3-isoquinolinecarboxamide.png "(3S,4aS,8aS)-2-[(2R,3R)-3-[(3-Amino-2-hydroxy-4-phenythiobutyl]-decahydro-N-(2-hydroxy-1,1-dimethylethyl)-3-isoquinolinecarboxamide")
Parent: Nelfinavir
![(3S,4aS,8aS)-2-[(2R,3R)-3-Amino-2-hydroxy-4-(phenylthio)butyl]-N-(1,1-dimethylethyl)decahydro-3-isoquinolinecarboxamide](https://veeprho.com/wp-content/uploads/2024/09/VE0021636-3S-4aS-8aS-2-2R-3R.png "(3S,4aS,8aS)-2-[(2R,3R)-3-Amino-2-hydroxy-4-(phenylthio)butyl]-N-(1,1-dimethylethyl)decahydro-3-isoquinolinecarboxamide")
Parent: Nelfinavir
![(3S,4aS,8aS)-2-[(2R,3R)-3-Amino-2-hydroxy-4-phenythiobutyl]-decahydro-3-isoquinolinecarboxylic Acid](https://veeprho.com/wp-content/uploads/2024/09/VE0021640-phenythiobutyl-decahydro-3-isoquinolinecarboxylic-Acid.png "(3S,4aS,8aS)-2-[(2R,3R)-3-Amino-2-hydroxy-4-phenythiobutyl]-decahydro-3-isoquinolinecarboxylic Acid")
Parent: Nelfinavir
Parent: Nelfinavir
Parent: Nelfinavir
Bulk nelfinavir and finished formulations are characterized and controlled by chromatography and mass spectrometry methods that quantify known related compounds and unspecified impurities. Common related compounds observed during synthesis and metabolism include desethyl-nelfinavir, hydroxy-nelfinavir (M8), dehydro and N-oxide derivatives; these are routinely monitored. Typical manufacturer specification ranges used in many product dossiers set limits such that individual identified impurities are generally controlled at or below approximately 0.5 percent relative to the API and the total impurities pool is commonly limited to about 1.0 to 2.0 percent, with tighter limits applied to genotoxic or structurally critical degradants. Exact impurity identities, acceptance criteria, analytical procedures and reporting thresholds vary by manufacturer and regulatory authority, so batch-specific certificates of analysis and pharmacopoeial monographs should be consulted for definitive values.
Nelfinavir is used as part of combination antiretroviral therapy to reduce HIV viral load and delay disease progression by inhibiting HIV protease and preventing production of mature infectious virus particles.
Nelfinavir is still used in some settings, particularly where other protease inhibitors are not available or where specific clinical considerations apply, but its use has declined in many regions because of newer agents with improved efficacy, tolerability and resistance profiles; availability and preferred use depend on local treatment guidelines.
Nelfinavir is a protease inhibitor that binds to the active site of the HIV-1 protease enzyme, blocking cleavage of Gag and Gag-Pol polyprotein precursors, which prevents viral maturation and production of infectious virions; the drug is metabolized to an active hydroxy metabolite (M8) that contributes to antiviral activity.
Cost varies widely by country, formulation, brand versus generic supply, and payer coverage; in many regions the original branded product may no longer be marketed and generic prices can range from low monthly costs in countries with generic programs to several hundred or more dollars per month in settings without subsidized access; consult local pharmacies, wholesalers or healthcare payers for current pricing.
